Zak Ortho
$11.4K 116 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Maxx Health Inc
Maxx Health Inc reported $11,454.08 across General Payments, Research, and Ownership to 27 physicians and teaching hospitals across 27 transactions.
- $11.5K Below-median payer
- All-tracks total
- 27 Below-median volume
- Transactions
- 27 Below-median reach
- Recipients
- +$9.6K
- General Payments vs PY2023
Maxx Health Inc reported $11,454.08 across all CMS Open Payments tracks (General + Research + Ownership) to 27 physicians and teaching hospitals in Program Year 2024 - ranking #1626 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $11,454.08, averaging $424.23 per recipient.
Maxx Health Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer maxx-health-inc Maxx Health Inc
$11.5K · #1626/1,925 · 0.0% industry · PY2024
- TOT $11.5K
- RANK #1626
- SHARE 0.0%
- TXN 27
- RCP 27
- CAT 2
- GEN $11.5K
- ΔGEN +$9.6K
- TOP1 39.8%
- PY 2024
Volume peers
Nearest volume peer: Zak Ortho ($11.4K)
Maxx Health Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Maxx Health Inc's CMS-reported General Payments increased by $9.6K (+523.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MAXX HEALTH INCPY2023: MAXX HEALTH INCPY2024: Maxx Health Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,835.98
- PY2024
- $11,454.08
What the Data Shows for Maxx Health Inc
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Maxx Health Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $9.3K, accounting for 81.6% of this company's General Payments and 3 transactions.
General Payment Breakdown by Type
"Consulting Fee" leads Maxx Health Inc's 2-category general-payment breakdown at $9.3K, 81.6% of the reported total.
How Maxx Health Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $9.3K | 3 | 81.6% |
| Food and Beverage | $2.1K | 24 | 18.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $10,222.89 (89.3%) of $11,454.08 in this company's General Payments records across 17 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Maxx Health Inc
The five named recipients with the highest reported General Payments from this company
- 1
Alon Antebi
$4,557.63 across 2 reported transactions
- 2
Justin Sherfey
$4,213.74 across 3 reported transactions
- 3
Scott Bleazey
$1,038.99 across 4 reported transactions
- 4
Andrew Hsiao
$233.71 across 2 reported transactions
- 5
Richard Chang
$178.82 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Maxx Health Inc ranks #1626 of 1,925 by total payments (bottom 16% by spend) but is notably more concentrated than that alone would suggest -- #563 of 1,838 by HHI (top 31% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Cook Research Incorporated : $288.6K total payments, HHI 3073
- Delphinus Medical Technologies, Inc. : $435.0K total payments, HHI 3070
- Perfuze Limited : $36.4K total payments, HHI 3056
- Medicaroid, Inc. : $3.1K total payments, HHI 3056
- Bard Access Systems, Inc. : $278.7K total payments, HHI 3052
- Den-Mat Holdings, LLC : $35.9K total payments, HHI 3047
- Maxx Health Inc (this company) : $11.5K total payments, HHI 3036
- Reapplix Inc. : $101.7K total payments, HHI 3032
- McKesson Specialty Care Distribution, LLC : $271.93 total payments, HHI 3010
- Moon Surgical : $46.8K total payments, HHI 3007
- Elekta AB (publ) : $740.86 total payments, HHI 3002
- Ingeniumspine, LLC : $13.0K total payments, HHI 2996
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Maxx Health Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Maxx Health Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Maxx Health Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Xenco Medical LLC
$11.5K 5 recipients
Compare payment profiles
Biolase MG LLC
$11.5K 13 recipients
Compare payment profiles
Biobeat USA Inc.
$11.6K 85 recipients
Compare payment profiles
Greiner Bio-One North America, Inc.
$11.6K 33 recipients
Compare payment profiles
EnableCV Inc.
$11.6K 73 recipients
Compare payment profiles
Put this to use
Maxx Health Inc ranks #1626 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Maxx Health Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.